Advertisement

Topics

$SGEN #Takeda ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma https://www.businesswire.com/news/home/20180921005364/en/Seattle-Genetics-Announces-ADCETRIS%C2%AE-Brentuximab-Vedotin-Approval …

11:50 EDT 21 Sep 2018 | Odi Bruckman

ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma https://www.businesswire.com/news/home/20180921005364/en/Seattle-Genetics-Announces-ADCETRIS%C2%AE-Brentuximab-Vedotin-Approval …

Original Article: $SGEN #Takeda ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma https://www.businesswire.com/news/home/20180921005364/en/Seattle-Genetics-Announces-ADCETRIS%C2%AE-Brentuximab-Vedotin-Approval …

NEXT ARTICLE

More From BioPortfolio on "$SGEN #Takeda ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma https://www.businesswire.com/news/home/20180921005364/en/Seattle-Genetics-Announces-ADCETRIS%C2%AE-Brentuximab-Vedotin-Approval …"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...